Abstract
In this chapter, we describe model systems to study leukemia driven by the Abelson oncogene. In people, the Abelson oncogene results from the chromosomal translocation t(9;22)(q34;q11) that is found in more than 90 % of all human chronic myeloid leukemia (CML) patients and in 20–25 % of patients suffering from acute lymphoid leukemia (ALL). This translocation is also called Philadelphia chromosome and encodes the BCR/ABL oncogene, a constitutive active tyrosine kinase. BCR/ABL renders hematopoietic cells independent from exogenous growth-stimulatory signals by continuously engaging signaling pathways including JAK-STAT signaling and the MAPK pathway. The enforced expression of BCR/ABL suffices to transform hematopoietic cells which made it to one of the best studied model systems in the field. Here we present methods to study BCR/ABL-triggered leukemia and solid lymphoid tumor formation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Chan LC, Karhi KK, Rayter SI et al (1987) A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 325:635–637
Lichty BD, Keating A, Callum J et al (1998) Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol 103:711–715
Clark SS, McLaughlin J, Crist WM et al (1987) Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 235:85–88
Chung SW, Wong PM, Durkin H et al (1991) Leukemia initiated by hemopoietic stem cells expressing the v-abl oncogene. Proc Natl Acad Sci U S A 88:1585–1589
Vesely MD, Kershaw MH, Schreiber RD et al (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235–271
Chen M, Gallipoli P, DeGeer D et al (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Canc Inst 105:405–423
Warsch W, Grundschober E, Berger A et al (2012) STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget 3:1669–1687
Berger A, Hoelbl-Kovacic A, Bourgeais J et al (2013) PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia 28:629–641
Putz EM, Gotthardt D, Hoermann G et al (2013) CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep 4:437–444
Kollmann K, Heller G, Schneckenleithner C et al (2013) A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 24:167–181
Hoelbl A, Kovacic B, Kerenyi MA et al (2006) Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 107:4898–4906
Warsch W, Kollmann K, Eckelhart E et al (2011) High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117:3409–3420
Friedbichler K, Kerenyi MA, Kovacic B et al (2010) Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 116:1548–1558
Kollmann K, Heller G, Ott RG et al (2011) c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5′ region of Cdk6. Blood 117:4065–4075
Hantschel O, Warsch W, Eckelhart E et al (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8:285–293
Hoelbl A, Schuster C, Kovacic B et al (2010) Stat5 is indispensable for the maintenance of bcr/abl -positive leukaemia. EMBO Mol Med 2:98–110
Kovacic B, Stoiber D, Moriggl R et al (2006) STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10:77–87
Ott RG, Simma O, Kollmann K et al (2007) JunB is a gatekeeper for B-lymphoid leukemia. Oncogene 26:4863–4871
Rosenberg N, Baltimore D (1976) A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J Exp Med 143:1453–1463
Serunian LA, Rosenberg N (1986) Abelson virus potentiates long-term growth of mature B lymphocytes. Mol Cell Biol 6:183–194
Kovacic B, Hoelbl A, Litos G et al (2012) Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med 4:283–297
Baron F, Turhan AG, Giron-Michel J et al (2002) Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 99:2107–2113
Stoiber D, Kovacic B, Schuster C et al (2004) TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 114:1650–1658
Acknowledgments
The authors are grateful to all current and former lab members of the Institute of Pharmacology and Toxicology at the University of Veterinary Medicine, Vienna. We are indebted to Sabine Fajmann for excellent technical assistance and all animal caretakers for taking excellent care of the mice. We further thank Mathias Müller, Birgit Strobl, Thomas Decker, Richard Moriggl, Robert Eferl, Emilio Casanova, and Dagmar Stoiber for valuable scientific input. This work was supported by the Austrian Science Foundation (FWF) by two grants to V.S. (SFB F28 and SFB F47).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Schneckenleithner, C., Hoelbl-Kovacic, A., Sexl, V. (2015). Modeling BCR/ABL-Driven Malignancies in the Mouse. In: Eferl, R., Casanova, E. (eds) Mouse Models of Cancer. Methods in Molecular Biology, vol 1267. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2297-0_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2297-0_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2296-3
Online ISBN: 978-1-4939-2297-0
eBook Packages: Springer Protocols